Jane Street
ATRA icon

Jane Street’s Atara Biotherapeutics ATRA Stock Holding History

Jane Street’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,400
Closed -$321K – 9100
2022
Q3 		$321K Buy
+3,400
New +$382K ﹤0.01% 7470
2021
Q1 		– Sell
-572
Closed -$281K – 9063
2020
Q4 		$281K Buy
+572
New +$264K ﹤0.01% 6501

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jane Street's ATRA Position: Q2 2026 in Review

Jane Street reduced its Atara Biotherapeutics (ATRA) stake by 10% in Q2 2026, selling an estimated $28.1K and leaving 30,345 shares worth $348K. The position accounts for ﹤0.01% of the portfolio, ranked #8876.

Jane Street first reported a position in ATRA in Q3 2015 and has held it in 22 quarters since. The position peaked at $1.4M in Q3 2020. 36 funds tracked by Wall St. Rank hold ATRA as of Q2 2026.

  • Jane Street held 30,345 shares of Atara Biotherapeutics worth $348K as of Q2 2026.
  • Jane Street sold 3,525 Atara Biotherapeutics shares in Q2 2026, an estimated $28.1K.
  • Atara Biotherapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #8876 holding.
  • Jane Street first reported a position in Atara Biotherapeutics in Q3 2015 and has held it in 22 quarters since.
  • Jane Street's Atara Biotherapeutics position peaked at $1.4M in Q3 2020.
  • 36 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.